Shareholders of Vistagen Therapeutics Urged to Act Before Class Action Deadline Approaches

Vistagen Therapeutics Class Action Notice

As Vistagen Therapeutics, Inc. (NASDAQ: VTGN) faces increasing scrutiny regarding its past financial disclosures, investors are urged to be aware of approaching legal deadlines. Faruqi & Faruqi, LLP, a prominent national securities law firm, has recently issued a reminder concerning the pivotal March 16, 2026 deadline for shareholders to participate as lead plaintiffs in a federal securities class action lawsuit against the company.

Background of Vistagen and its Legal Challenges

Vistagen is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. However, the firm has found itself embroiled in legal issues following its announcement of negative results from a crucial clinical trial. This trial was centered around fasedienol, a drug intended for the treatment of social anxiety disorder (SAD). On December 17, 2025, Vistagen revealed that the study did not meet its primary efficacy endpoint, leading to a staggering drop of over 81% in the company’s stock price, which opened at a mere $0.88 per share the following day.

The lawsuit claims that Vistagen and its executives made misleading statements regarding the potential for success in the PALISADE-3 clinical trial, thereby influencing investors to purchase shares at inflated prices while concealing detrimental information. The lack of transparency regarding the trial’s efficacy has left many shareholders facing significant financial losses.

Shareholder Encouragement to Act

Josh Wilson, a senior partner at Faruqi & Faruqi, has directly communicated with affected investors, encouraging them to seek legal counsel to discuss their rights and potential recourse. This situation illustrates the importance of awareness and swift action among investors who experienced financial damage due to the alleged misrepresentations by Vistagen.

Interested investors who acquired Vistagen securities between April 1, 2024, and December 16, 2025, have the opportunity to join the class action, which aims to hold the company accountable for its actions. This is an opportunity for shareholders to potentially recover some of their losses by participating in the lawsuit as lead plaintiffs, provided they meet the criteria set by the court.

Next Steps for Investors

For those contemplating joining the action, it is critical to understand the process of becoming a lead plaintiff. The court will select the lead plaintiff based on who has the largest financial stake in the outcome of the case and is considered typical of the other class members affected.

Faruqi & Faruqi is committed to supporting shareholders through this challenging period. They are inviting anyone with relevant information, including whistleblowers, to come forward. Additionally, the law firm emphasizes that participation in the upcoming legal proceedings does not preclude individuals from retaining their rights as shareholders.

Conclusion

The deadline of March 16, 2026, weighs heavily on the minds of many Vistagen investors as they weigh their options in light of recent developments. For those affected, taking timely action may be essential in navigating their legal rights in response to the adverse effects of Vistagen’s alleged mismanagement and lack of transparency.

For more information or to speak with legal representatives regarding this class action, affected investors can reach out to Faruqi & Faruqi directly through their contact channels. [Contact Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for guidance.]